Abstract: The invention relates to novel chemical entities that act as thromboxane (TX) A2 receptor, or T prostanoid receptor (TP), antagonists and to their use in the treatment of human diseases in which thromboxane (TX) A2 and of all other agents that act as incidental ligands of TP play a role. Compounds are-represented by the formula (I): wherein: R1 is selected from the group consisting of a difluoromethoxy group, a trifluoromethoxy group, a difluoromethyl group, a primary amide, a secondary amide group, a tertiary amide group, and a nitrile group; and R2 is selected from the group consisting of an alkyl group of 6 or fewer carbons and a halogenated alkyl group of 6 or fewer carbons, wherein R2 is not tert butyl, or a pharmaceutically acceptable salt thereof.